Echinatin protects from ischemic brain injury by attenuating NLRP3-related neuroinflammation

Neurochem Int. 2024 May:175:105676. doi: 10.1016/j.neuint.2024.105676. Epub 2024 Feb 7.

Abstract

Background: Microglia-mediated neuroinflammation is the major contributor to the secondary brain injury of ischemic stroke. NLRP3 is one of the major components of ischemia-induced microglial activation. Echinatin, a chalcone found in licorice, was reported to have the activity of anti-inflammation and antioxidant. However, the relative study of echinatin in microglia or ischemic stroke is still unclear.

Methods: We intravenously injected echinatin or vehicle into adult ischemic male C57/BL6J mice induced by 60-min transient middle cerebral artery occlusion (tMCAO). The intraperitoneal injection was performed 4.5 h after reperfusion and then daily for 2 more days. Infarct size, blood brain barrier (BBB) leakage, neurobehavioral tests, and microglial-mediated inflammatory reaction were examined to assess the outcomes of echinatin treatment. LPS and LPS/ATP stimulation on primary microglia were used to explore the underlying anti-inflammatory mechanism of echinatin.

Results: Echinatin treatment efficiently decreased the infarct size, alleviated blood brain barrier (BBB) damage, suppressed microglial activation, reduced the production of inflammatory factors (e.g., IL-1β, IL-6, IL-18, TNF-α, iNOS, COX2), and relieved post-stroke neurological defects in tMCAO mice. Mechanistically, we found that echinatin could suppress the NLRP3 assembly and reduce the production of inflammatory mediators independently of NF-κB and monoamine oxidase (MAO).

Conclusion: Based on our study, we have identified echinatin as a promising therapeutic strategy for the treatment of ischemic stroke.

Keywords: Echinatin; Ischemic stroke; Microglia; NLRP3 inflammasome; Neuroinflammation; tMCAO.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Brain Injuries* / drug therapy
  • Brain Ischemia* / complications
  • Brain Ischemia* / drug therapy
  • Brain Ischemia* / prevention & control
  • Chalcones*
  • Infarction / complications
  • Infarction / drug therapy
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy
  • Ischemic Stroke* / drug therapy
  • Lipopolysaccharides
  • Male
  • Mice
  • Microglia
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Neuroinflammatory Diseases
  • Reperfusion Injury* / drug therapy

Substances

  • echinatin
  • Chalcones
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Lipopolysaccharides
  • Anti-Inflammatory Agents